Amicus Therapeutics

This morning, Amicus announced its third quarter 2024 financial results. Members of the Amicus senior leadership team will host a conference call and webcast at 8:30 a.m. ET.?https://lnkd.in/gRRrTgiz

Hear from Paul Howard, PhD Senior Director, Public Policy, on the innovative insights he gathered at Global Genes last month. One of the major themes of the conference was the benefits of harnessing data sharing and AI to shorten the diagnostic odyssey and accelerate delivery of more effective treatment options for those living with rare diseases. Check out Paul’s blog on everything he learned. #AmicusCares?

Our Amicus Wellness Committee are the creators of an annual ‘Amicus Moves’ event, and this year, we had over 50 employees participate across Princeton and Marlow! ? As part of this year’s event, our Princeton office also got to hear from a wonderful guest speaker called Emma, who discussed the importance of mobility and exercise when living with a rare disease. ? A big thank you to all who volunteered their time and participated, especially those who joined us on our annual walk.?As part of this annual event, we also made significant contributions to the Princeton YMCA and Save the Children International. ? #AmicusCares

Our employees are integral to our mission to bringing innovative medicines to people living with rare diseases.? ? Learn more from Megan Bilson, our SVP, Global Talent Management on what makes Amicus a Great Place to Work.?https://bit.ly/3Ty2es3

We are?honored?to have?participated?in Global Genes: Week in Rare! Hearing the latest insights and innovations from across the rare disease space has only strengthened our commitment to pushing the boundaries of research and advocacy.?Collaborating with advocates, patients, and researchers is key to driving meaningful change for the rare disease community. #WeekinRARE #GlobalGenes

Our Chief People Officer, David Clark, responds to the excellent news that we’ve been ranked #18 on Fortune's Best Workplaces in Biotechnology and Pharmaceuticals for 2024. We invite you to learn more about career opportunities on our website, as well as our culture and benefits, here: https://lnkd.in/d7FbX2VZ #GreatPlacesToWork #AmicusCares

September marked another step forward for awareness as we honored Newborn Screening Awareness month. We are pleased to support the rare disease community in recognizing the importance of newborn screenings in the early detection and treatment of genetic and rare diseases. #2024NBS #NewbornScreening #AmicusCares

We’re excited to announce that Amicus Therapeutics has ranked #18 on Fortune’s Best Workplaces in Biotechnology and Pharmaceuticals for 2024! A heartfelt thank you to our amazing team for embodying our mission every day. We’re proud of what we’ve accomplished together and look forward to continuing our journey toward making a difference for people living with #rarediseases #BestBioPharmaWorkplaces #GreatPlacesToWork #AmicusCares https://bit.ly/3Ty2es3

We’re proud to be attending Global Genes: Week in Rare! We’re committed to advancing rare disease research and advocacy. Join us in connecting with the community and driving meaningful change for those affected by rare?diseases.?#WeekinRARE #GlobalGenes

At Amicus we are dedicated to making a profound impact on the lives of patients affected by #RareDisease. We are proud to share the recent contributions of our Chief Risk Officer, Patrik Florencio, and Chief Patient Advocate, Jayne Gershkowitz, in Healthcare Business Today, that underscores the vital role of Patient Advocacy Organizations (PAOs) and patient advocates in the rare disease community. PAOs and #PatientAdvocates are uniquely positioned to share their expertise, drawn from both professional and lived experiences, to improve #PatientCare. The article shines a light on the importance of collaboration between the industry and these critical stakeholders. We remain deeply committed to making meaningful impact on the lives of rare disease patients, ensuring that patient voices remain at the heart of everything we do. Read the full article here to learn more: https://bit.ly/3LYljPS #RareDisease #PatientAdvocacy #Leadership #Compliance #Collaboration